Maravai Lifesciences Holds Annual Shareholders Meeting

Maravai Lifesciences Holdings ( (MRVI) ) has issued an announcement.

On May 22, 2025, Maravai LifeSciences Holdings, Inc. conducted its Annual Meeting of Shareholders. During the meeting, shareholders elected directors for three-year terms, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the compensation of the company’s named executive officers on a non-binding advisory basis.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.

Spark’s Take on MRVI Stock

According to Spark, TipRanks’ AI Analyst, MRVI is a Neutral.

Maravai Lifesciences Holdings scores 47.1, reflecting significant financial challenges with declining revenue and profitability. The company shows potential in growth and innovation, evidenced by exceeding revenue expectations and advancements in mRNA technologies. However, negative earnings and profitability issues weigh heavily on its valuation and technical indicators, making it a high-risk investment at present.

To see Spark’s full report on MRVI stock, click here.

More about Maravai Lifesciences Holdings

Maravai LifeSciences Holdings, Inc. operates in the life sciences industry, providing essential products and services that support the development of drug therapies, diagnostics, and novel vaccines. The company focuses on delivering innovative solutions to enhance the quality and efficiency of healthcare and research applications.

Average Trading Volume: 2,775,896

Technical Sentiment Signal: Sell

Current Market Cap: $567.9M

For a thorough assessment of MRVI stock, go to TipRanks’ Stock Analysis page.